Trial Profile
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients with Venous Thromboembolism in Europe - ETNA-VTE-Europe
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Acronyms ETNA-VTE; ETNA-VTE-Europe
- Sponsors Daiichi Sankyo Europe; Daiichi Sankyo Inc
- 09 Apr 2021 Status changed from active, no longer recruiting to completed.
- 14 Jul 2020 According to a Daiichi Sankyo media release results from this trial were presented during the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress.
- 14 Jul 2020 Results published in the Media Release